Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $9 | $18 | $75 |
| - Cash | $1 | $5 | $7 | $16 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $4 | $11 | $59 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$11 | -$19 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$12 | -$11 | -$27 | -$11 |
| % Margin | – | – | – | – |
| EPS Diluted | -96.75 | -212 | -42.5 | -373 |
| % Growth | 54.4% | -398.8% | 88.6% | – |
| Operating Cash Flow | -$11 | -$8 | -$10 | -$9 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$11 | -$8 | -$10 | -$9 |